Royalty Pharma plc (NASDAQ:RPRX) Receives $42.00 Average PT from Analysts

Royalty Pharma plc (NASDAQ:RPRX) has been assigned a consensus recommendation of “Moderate Buy” from the five research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $42.00.

RPRX has been the topic of several research analyst reports. Morgan Stanley raised their price target on shares of Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a research report on Thursday, July 11th. StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, August 13th. The Goldman Sachs Group upped their price target on Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Finally, UBS Group lowered Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price objective on the stock. in a report on Monday, June 3rd.

Royalty Pharma Price Performance

Shares of NASDAQ:RPRX opened at $27.49 on Thursday. The company has a market cap of $16.42 billion, a price-to-earnings ratio of 20.52, a PEG ratio of 3.96 and a beta of 0.46. The business has a 50 day moving average price of $27.12 and a 200 day moving average price of $28.24. The company has a quick ratio of 9.35, a current ratio of 9.35 and a debt-to-equity ratio of 0.78. Royalty Pharma has a twelve month low of $25.20 and a twelve month high of $31.66.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.01. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. The company had revenue of $537.00 million during the quarter, compared to analyst estimates of $600.83 million. During the same period in the previous year, the company earned $0.85 earnings per share. Research analysts predict that Royalty Pharma will post 4 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 13th. Shareholders of record on Friday, August 16th will be issued a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 3.06%. The ex-dividend date is Friday, August 16th. Royalty Pharma’s payout ratio is 62.69%.

Hedge Funds Weigh In On Royalty Pharma

Hedge funds have recently modified their holdings of the stock. Swedbank AB bought a new stake in Royalty Pharma in the first quarter valued at $251,461,000. Norges Bank acquired a new stake in shares of Royalty Pharma in the 4th quarter valued at $119,740,000. New South Capital Management Inc. bought a new stake in shares of Royalty Pharma in the 1st quarter worth about $44,384,000. ADAR1 Capital Management LLC acquired a new stake in shares of Royalty Pharma during the 4th quarter worth about $37,130,000. Finally, Patient Capital Management LLC bought a new position in Royalty Pharma during the 4th quarter valued at about $35,247,000. 54.35% of the stock is owned by institutional investors and hedge funds.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.